CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 24 enrolled
Drug / intervention
Umbilical Cord Mesenchymal Stem Cells + Heparin along with best supportive care. +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04355728
NCT04355728Phase 2Completed

Umbilical Cord-derived Mesenchymal Stem Cells for COVID-19 Patients With Acute Respiratory Distress Syndrome (ARDS)

Camillo Ricordi·interventional·Posted Apr 21, 2020·Updated Dec 6, 2021

In Brief

A Phase 2 clinical trial evaluating Umbilical Cord Mesenchymal Stem Cells + Heparin along with best supportive care. and Vehicle + Heparin along with best supportive care for Corona Virus Infection and 4 related conditions. Completed, enrolled 24 participants across 1 site.

Detailed Summary

The purpose of this research study is to learn about the safety and efficacy of human umbilical cord derived Mesenchymal Stem Cells (UC-MSC) for treatment of COVID-19 Patients with Severe Complications of Acute Lung Injury/Acute Respiratory Distress Syndrome (ALI/ARDS).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
202120222023202420252026
First PostedApr 21, 2020
Enrollment StartApr 25, 2020
Primary CompletionOct 31, 2020
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 6.2 years ago

Interventions

Umbilical Cord Mesenchymal Stem Cells + Heparin along with best supportive care.biological

UC-MSC will be administered at 100x10\^6 cells/infusion administered intravenously in addition to the standard of care treatment.

Vehicle + Heparin along with best supportive careother

Best supportive care treatment per the treating hospital protocol.